التفاصيل البيبلوغرافية
| العنوان: |
Myocardial dysfunction in long-term breast cancer survivors treated at ages 40-50 years. |
| المؤلفون: |
Jacobse, Judy N., Steggink, Lars C., Sonke, Gabe S., Schaapveld, Michael, Hummel, Yoran M., Steenbruggen, Tessa G., Lefrandt, Joop D., Nuver, Janine, Crijns, Anne P.G., Aleman, Berthe M.P., Meer, Peter, Gietema, Jourik A., Leeuwen, Flora E., van der Meer, Peter, van Leeuwen, Flora E |
| المصدر: |
European Journal of Heart Failure; Feb2020, Vol. 22 Issue 2, p338-346, 9p, 5 Charts, 1 Graph |
| مصطلحات موضوعية: |
CANCER patients, BREAST cancer, HEART failure, VENTRICULAR ejection fraction, HOT flashes, ANTHRACYCLINES, LOGISTIC regression analysis, LEFT heart ventricle, RESEARCH, LEFT ventricular dysfunction, RESEARCH methodology, ARTHRITIS Impact Measurement Scales, MEDICAL cooperation, EVALUATION research, COMPARATIVE studies, RESEARCH funding, HEART physiology, STROKE volume (Cardiac output), PEPTIDE hormones, BREAST tumors, PEPTIDES, DISEASE complications |
| مستخلص: |
Aims: Anthracyclines increase heart failure (HF) risk, but the long-term prevalence of myocardial dysfunction in young breast cancer (BC) survivors is unknown. Early measures of left ventricular myocardial dysfunction are needed to identify BC patients at risk of symptomatic HF.Methods and Results: Within an established cohort, we studied markers for myocardial dysfunction among 569 women, who were 5-7 years (n = 277) or 10-12 years (n = 292) after BC treatment at ages 40-50 years. Left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS) were assessed by echocardiography. N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured in serum. Associations between patient-related and treatment-related risk factors and myocardial dysfunction were evaluated using linear and logistic regression. Median ages at BC diagnosis and cardiac assessment were 46.7 and 55.5 years, respectively. Anthracycline-treated patients (n = 313), compared to the no-anthracycline group (n = 256), more often had decreased LVEF (10% vs. 4%), impaired GLS (34% vs. 27%) and elevated NT-proBNP (23% vs. 8%). GLS and LVEF declined in a linear fashion with increasing cumulative anthracycline dose (GLS: +0.23 and LVEF: -0.40 per cycle of 60 mg/m2 ; P < 0.001) and GLS was worse for patients with left breast irradiation. The risk of NT-proBNP >125 ng/L was highest for patients who received 241-300 mg/m2 anthracycline dose compared to the no-anthracycline group (odds ratio: 3.30, 95% confidence interval: 1.83-5.96).Conclusion: Impaired GLS and increased NT-proBNP levels are present in a substantial proportion of young BC survivors treated with anthracyclines. Whether this will lead to future cardiac disease needs to be evaluated by longitudinal assessment. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Heart Failure is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder